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Progression of human cutaneous primary melanoma is, among others, accompanied by de novo expression of
activated leukocyte cell adhesion molecule (ALCAM/CD166) and enhanced activity of proteolytic cascades in the
invasive, vertical growth phase (VGP) of lesions. The homophilic cell adhesion function of wild-type ALCAM
mediates homotypic clustering of melanoma cells and would, thus, antagonize cell release from the primary tumor,
an early prerequisite for metastasis. Stable transfection of a transmembrane, amino-terminally truncated ALCAM
(DN-ALCAM) into metastatic cells diminished cell clustering mediated by wild-type ALCAM. We have addressed the
biological effects of DN-ALCAM on tumorigenicity and found that the relief of cell clustering constraints promoted
motility in vitro and the transition from expansive tumor growth to tissue invasion in reconstructed skin in culture.
In a transplant tumor model, the changes were reﬂected in reduced subcutaneous tumor growth and in accelerated,
spontaneous lung metastasis. These data indicate that the intact cell adhesion function of ALCAM may both favor
primary tumor growth and represent a rate-limiting step for tissue invasion from VGP melanoma. ALCAM induction
could, thus, provide an attractive target for proteolysis as a part of a more complex cellular program that couples
growth and migration and facilitates dissemination.
Key words: ALCAM/CD166/cell motility/melanoma metastasis/proteolytic mimicry/reconstructed skin
J Invest Dermatol 122:1293 –1301, 2004
Cutaneous melanoma is a malignant tumor of the pigmen-
ted cells (Chin et al, 1998). The current lifetime risk for de-
veloping any kind of melanoma is one in 75 for a Caucasian
in the United States and this incidence will continue to rise
for at least the next 10–20 y (Rigel et al, 1996). Melanoma is
notorious for an early metastasizing phenotype and lack of
response to current therapeutics. This is reflected in poor
5-y survival rates (o10%) of patients diagnosed with ad-
vanced primary melanoma (Herlyn, 1993; Balch et al, 2001).
Understanding the molecular events that mark the transition
from non-metastasizing to metastasizing melanoma is,
therefore, of utmost importance.
In about one-third of the cases, melanomagenesis pro-
gresses through a series of steps starting with melanoblasts,
melanocytes, or benign melanocytic nevi and develops via
radial (RGP) and vertical growth phase (VGP) primary
tumors to metastases (Clark et al, 1984; Herlyn, 1999).
During the past 15 y, several adhesion molecules that are
expressed in specific stages of melanoma progression have
been identified, e.g., cadherins, integrins, and immunoglo-
bulin cell adhesion molecules (Ig-CAM; for a review see
Meier et al, 1999). Expression of activated leukocyte cell
adhesion molecule (ALCAM/MEMD/CD166) distinguishes
the invasive and metastasizing VGP melanoma from non-
invasive and non-metastasizing RGP melanoma (Van
Kempen et al, 2000). ALCAM expression can only be
detected in a subset of cells at the invasive front of these
malignant tumors. Additionally, ALCAM expression is
observed in various carcinoma cell lines including breast,
prostate, colon, and bladder (Degen et al, 1998 and our
unpublished data). Therefore, elucidating the functional
involvement of ALCAM in melanoma progression may also
provide new insights into other types of cancer.
ALCAM is a transmembrane protein and a member of the
Ig superfamily (reviewed in Isake and Horton, 2000; Swart,
2002). It has approximately 80% homology with the chicken
neural cell adhesion molecule BEN/SC1/DM-GRASP (Burns
et al, 1991; Tanaka et al, 1991; Pourquie et al, 1992) and
approximately 27% identity and 38% similarity with the
human melanoma cell adhesion molecule MUC18/Mel-CAM/
CD146 (Lehmann et al, 1989). ALCAM, first identified as a
CD6 ligand (Bowen et al, 1995), is involved in hematopoiesis
(Cortes et al, 2000; Nelissen et al, 2000a), neurite extension
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(Sekine-Aizawa et al, 1998), osteogenesis (Bruder et al,
1998), and embryonal implantation in the uterus (Fujiwara et
al, 2003). Both heterophilic (ALCAM–CD6) interactions and
homophilic (ALCAM–ALCAM) interactions have been de-
scribed (Bowen et al, 1995; Degen et al, 1998; Nelissen et al,
2000b). In human melanoma cell lines, ALCAM facilitates
tumor cell aggregation via homophilic interactions (Degen et
al, 1998). ALCAM comprises five extracellular Ig domains
(D1-5): two amino-terminal, membrane-distal, variable (V-)
type domains followed by three membrane-proximal,
constant (C2-) type domains (VVC2C2C2). It further com-
prises a transmembrane domain and a short carboxy-
terminal cytoplasmic tail. ALCAM-mediated intercellular
adhesion involves interactions between opposing amino-
terminal D1 domains of receptor molecules on different
cells. ALCAM-mediated adhesion is further strengthened by
lateral oligomerization of neighboring molecules on the cell
surface involving the membrane proximal domains D4-5
(Van Kempen et al, 2001). This bimodular structure supports
the formation of a tight network of ALCAM interactions in
regions of cell–cell contact (Fig 1A). The expression of
ALCAM at the invasive front of VGP melanoma lesions,
however, poses the paradox of strong cellular adhesion
in the very part of the tumor notorious for tumor cell
dissemination and subsequent metastasis.
Modulation of cell adhesion is required to pass through
the successive stages of the metastatic cascade. One may
anticipate that an increase in homotypic tumor cell cluster-
ing should, presumably, hamper cell release from a primary
lesion. By contrast, the formation of tumor cell emboli could
favor cell survival during later stages of metastasis. To gain
insight in the positive and negative effects of homotypic
cell clustering on tumorigenesis, we have compared the
malignant properties of BLM, a metastatic melanoma cell
line with endogenous expression of wild-type ALCAM, and
a series of BLM clones that additionally express recombi-
nant, amino-terminally truncated ALCAM (DN-ALCAM) to
attenuate homotypic cell clustering (Fig 1B). This analysis
revealed dual effects, as diminished cell clustering was
apparently unfavorable for primary tumor growth whereas it
enhanced cell motility and metastasis.
Results
Reduced ALCAM-mediated cell adhesion increases
melanoma cell motility To interfere with homotypic cell
clustering we overexpressed a transmembrane, amino-
terminally truncated ALCAM construct (DN-ALCAM) in BLM
cells that endogenously express wild-type ALCAM (D1-5).
DN-ALCAM lacks the extracellular ligand-binding domains
D1-2 but retains the oligomerizing function of domains D3-
5. The truncated molecule, with an apparent molecular
mass of 90 kDa, interfered in the formation of a tight ALCAM
network, thereby reducing cellular adhesion in a concentra-
tion-dependent manner (Fig 2; compare Van Kempen et al,
2001). To test whether cells with reduced ALCAM-mediated
adhesion would have a more mobile phenotype as a
consequence of decreased anchoring to their neighbors,
an in vitro wound-healing assay was performed by inflicting
a ‘‘wound’’ on a confluent monolayer of cells. The time
interval needed to close the gap was monitored for control
and DN-ALCAM-transfected cells. It was observed that DN-
ALCAM expression by BLM cells slightly increased cell
motility compared with vector control cells (Fig 3). Trans-
fection of DN-ALCAM into 530 cells (a non-metastatic,
ALCAM-negative melanoma cell line) did not affect the
virtual lack of motility of these cells. Thus, reduction of wild-
type ALCAM-mediated cell-to-cell contacts increased cell
motility in vitro.
Attenuation of ALCAM cell adhesion and effects on
melanoma growth in skin reconstructs It is generally
accepted that loss of cell–cell adhesion and a concomitant
increase in cell motility favor the invasive potential of tumor
cells (Hanahan and Weinberg, 2000). Therefore, the invasive
capacity of melanoma cells expressing DN-ALCAM was
tested in skin reconstructs. Control cells transfected with
empty vector (BLM/CTRL, expressing wild-type ALCAM)
formed massive clusters of cells and band-like aggregates
within the epidermis at the epidermal–dermal junction and
in the upper dermis (Fig 4A). Complete disruption of the
epidermal architecture reflected the expansive and moder-
ately invasive growth phenotype of these BLM/CTRL cells.
In contrast, DN-ALCAM expressing BLM cells (BLM/DN-
ALCAM: expressing DN-ALCAM in addition to wild-type
ALCAM) displayed a highly invasive phenotype and loca-
lized in the dermis, thereby leaving the epidermis intact
(Fig 4B). These vertically oriented cells steadily migrated or
Figure 1
Model of cell–cell adhesion mediated by homophilic activated
leukocyte cell adhesion molecule (ALCAM)–ALCAM interactions.
Bimodular ALCAM network formation supports cell–cell interactions (A)
whereas DN-ALCAM disrupts the ALCAM network (B). (For a detailed
description: see the Introduction.)
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disseminated as slender tumor cell strands or single cells
deep into the dermal compartment (Fig 4C), whereas
individual, horizontally oriented BLM/CTRL cells moderately
invaded into the upper dermis (Fig 4A and D). Inhibition of
ALCAM-mediated cell clustering via DN-ALCAM, thus,
revealed the invading potential of the human melanoma
cell line BLM.
Partially impaired ALCAM-mediated adhesion and pri-
mary xenograft growth In order to study whether impair-
ing ALCAM-mediated cell adhesion by DN-ALCAM affects
tumorigenic properties, BLM/DN-ALCAM cells were sub-
cutaneously injected into nude mice. Monitoring local tumor
growth, it was observed that BLM/DN-ALCAM cells dis-
played a delay in tumor take and decreased growth of
the subcutaneous tumors compared with BLM/CRTL cells
(Fig 5A). In additional control experiments, the transfection
of either wild-type ALCAM or DN-ALCAM into 530 mela-
noma cells did not significantly alter their subcutaneous
growth.
In cell culture, no differences were observed in cell pro-
liferation rates between BLM/DN-ALCAM and BLM/CRTL
cells (data not shown). Analysis of the tumors obtained
after euthanizing the mice (Fig 5B) disclosed neither
differences in cell proliferation indices (Iproliferation, F¼ 1.06,
p¼0.38, one-way analysis of variance), nor apoptosis
indices (Iapoptosis, F¼0.89, p¼0.44, one-way analysis of
variance) nor necrosis (not shown) indicating that the
decreased primary tumor growth cannot be ascribed to a
disrupted balance between cell gain and cell death.
Partially impaired ALCAM-mediated adhesion and lung
metastasis An alternative explanation for reduced primary
tumor growth could be provided by the difference in the
migratory potential of the cells as observed in reconstructed
skin in culture (Fig 3). To obtain a more complete picture and
Figure 2
DN-ALCAM expressed in the wild-type ALCAM expressing cell line
BLM, reduces cell aggregation in a concentration-dependent
manner. (A) Independently isolated transfectants of BLM cells over-
expressing DN-ALCAM (BLM/DN-ALCAM-1, -2, and -3) were gener-
ated from the parental cell line BLM endogenously expressing
wild-type ALCAM. Expression levels of the truncated molecule were
determined via flow cytometry employing mAb AZN-L50 (4 mg per mL)
that recognizes the membrane proximal domains D4-5. mAb AZN-L50
is therefore suitable for identifying both wild-type ALCAM and
ectopically expressed DN-ALCAM. Wild-type ALCAM levels are not
affected by overexpression of DN-ALCAM (see western blotting data in
Van Kempen et al, 2001). Consequently, the shift of the fluorescence
peaks relative to the control is a quantitative measure for the ratio
between wild-type ALCAM and DN-ALCAM levels. (B) The established
cell lines expressing DN-ALCAM (BLM/DN-ALCAM-1, -2, and -3) were
subjected to an in vitro aggregation assay and analyzed by flow
cytometry. Expression of DN-ALCAM reduced the aggregation capacity
of these cells as compared with the vector control cell line (BLM/CTRL)
in a concentration-dependent manner and DN-ALCAM, thus, func-
tioned as a dominant-negative molecule with respect to ALCAM-
mediated cell clustering. ALCAM, activated leukocyte cell adhesion
molecule; mAb, monoclonal antibody.
Figure3
Ectopic DN-ALCAM increases cell motility. (A) Tumor cells expres-
sing either endogenous wild-type ALCAM alone (BLM/CTRL) or in
combination with ectopic DN-ALCAM (BLM/DN-ALCAM-2) were grown
to confluence in a tissue culture dish. A ‘‘wound’’ was inflicted in the
monolayer of cells using a pipette tip. Time was monitored for the cells
to close the gap. (B) Gap-width (in arbitrary units, a.u.) is plotted as
function of time. DN-ALCAM expressing cells demonstrated an
increase in cell mobility as the gap is closed more rapidly. ALCAM,
activated leukocyte cell adhesion molecule.
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to collect larger numbers of subcutaneous tumors of
different sizes, we varied the lifetime of mice after
inoculation of the tumor cells. An overview of all data
(scoring subcutaneous tumor size, metastasis rate, and
lifetime after subcutaneous inoculation of the melanoma
cells) is presented in Table I. Rapid tumor cell dissemination
may explain the reduced growth of subcutaneous tumors
derived from BLM/DN-ALCAM as these cells already gave
rise to lung metastasis in a considerable number of mice at
a relatively small tumor mass, i.e., less than 1.5 g, whereas
lung metastasis of the control cells occurred only at tumor
masses exceeding 3 g (Table I). The numbers in Table II
showed that the differences found in metastasis frequen-
cies were statistically significant (po0.05; w2 test). In addi-
tional control experiments, we found that transfection of
wild-type ALCAM or DN-ALCAM into 530 melanoma cells
did not alter the non-metastatic phenotype of these cells.
Our data suggest that subcutaneous tumor growth is rate
Figure 4
DN-ALCAM expressing BLM cells are more
invasive than control cells in skin recon-
structs. The growth properties of all BLM/DN-
ALCAM cell clones were tested in skin recon-
structs. Pictures shown in (B) and (C) are
representative for the growth properties of all
transfectants. (A) Vector control cells (BLM/
CTRL) formed clusters of cells and band-like
aggregates within the epidermis, at the epider-
mal–dermal junction and in the upper dermis.
Arrowheads show individual melanoma cells
infiltrating the dermis. Scale bar: 50 mm. (B)
DN-ALCAM expressing BLM cells all localized to
the dermis and did not form tumor cell clusters
or band-like tumor cell aggregates but steadily
invaded the deep dermis as slender tumor cell
strands or single cells. Sacle bar: 50 mm. (C) Skin
reconstructs with DN-ALCAM expressing BLM
cells displayed a vertical orientation of tumor
cells that steadily invaded the deep dermis.
Scale bar: 12.5 mm. (D) Horizontally oriented
BLM/CTRL cells displayed an expansive growth
in the epidermis and epidermal–dermal junction
without profound invasion. Scale bar: 12.5 mm.
ALCAM, activated leukocyte cell adhesion mo-
lecule.
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limiting for metastasis formation of control BLM cells, which
have a wild-type ALCAM cell adhesion function.
Subcutaneous tumor formation was hampered after
additional expression of DN-ALCAM and consequent atte-
nuation of BLM cell clustering (compare with Figs 2
and 5). Unexpectedly, diminished growth of subcutaneous
tumors was not accompanied by an apparent decrease
in malignancy (Table I). On the contrary, the number of
metastatic lesions in the lung sections scored by micro-
scopic analysis also revealed that the presence of DN-
ALCAM rather reduced the need of subcutaneous tumor
formation prior to metastasis. The number of metastatic
lesions was generally higher after inoculation of BLM/DN-
ALCAM cells (4.2 and 5.1 lung lesions on average per
positive mouse, respectively; Table II) than after inoculation
of control BLM cells (3.2 lung lesions on average per
positive mouse; Table II). These observations underscored
the interpretation that the recombinant generation of
DN-ALCAM in BLM cells accelerated the dissemination
process.
Discussion
Melanoma development advances from superficially
spreading tumor growth in the epidermis to subsequent
invasive growth into the dermis and culminates in the
formation of distant metastases. Human melanoma pro-
gression is accompanied by de novo expression of the
homophilic cell–cell adhesion molecule ALCAM/CD166 at
the invasive front of VGP tumors (Van Kempen et al, 2000).
It is generally accepted that onset of metastatic spread
implies release of cells from the primary tumor mass
(Hanahan and Weinberg, 2000). This poses a paradox since
the cell adhesion function of wild-type ALCAM actually
promotes tumor cell clustering and would, thus, antagonize
cell release from the primary tumor. Attenuation of cell
clustering promoted by wild-type ALCAM can be achieved
by expression of transmembrane, amino-terminally trun-
cated ALCAM (DN-ALCAM), which lacks the cell adhesion
function (Fig 1; Van Kempen et al, 2001). Here we show that
the resulting relief of clustering constraints favors tumor cell
motility in vitro (Figs 2 and 3) and the transition from
expansive tumor growth to rapid dermal invasion in
reconstructed skin in culture (Fig 4). Furthermore, the
presence of DN-ALCAM interferes with subcutaneous
Figure 5
DN-ALCAM expression in BLM cells with endogenous wild-type
ALCAM decreased local tumor growth and induced rapid metas-
tasis when inoculated into nude mice. (A) ALCAM-positive BLM cells
and BLM cells co-expressing ectopic DN-ALCAM were inoculated
subcutaneously (2.5  106 cells) and local tumor growth was mon-
itored. Animals were euthanized at indicated days post-inoculation ().
Local tumor growth is greatly reduced in DN-ALCAM expressing BLM
cells (BLM/DN-ALCAM-2): tumor take is clearly delayed and the
exponential growth of the tumor is decreased. (B) The decreased local
tumor growth is not due to altered cell proliferation or apoptosis. Cell
proliferation index (Iproliferation) was based upon overall MIB-1 expres-
sion in the xenografts (MIB-1-positive cells/total cells). No significant
differences were found comparing BLM/CTRL-derived xenografts with
BLM/DN-ALCAM xenografts (one-way analysis of variance, F¼1.06,
p¼0.38). In addition, levels of apoptosis (Iapoptosis) as measured by
TUNEL (TUNEL-positive cells with apoptotic morphology/total cells)
were not significantly different either (one-way analysis of variance,
F¼0.89, p¼ 0.44). ALCAM, activated leukocyte cell adhesion mole-
cule; TUNEL, TdT-mediated dUTP nick end labeling.
Table I. Subcutaneous tumor growth and metastasis of BLM melanoma cells in nude mice
BLM cells
Subcutaneous
tumor size
(weight, g)
Lifetime after
subcutaneous
injection (31 d)
Mice with
lung metastasis Lifetime after
subcutaneous
injection (442 d)
Mice with
lung metastasis
#/total % #/total %
Controls (w.t. ALCAM) o1.5 2 0/2 0 0 NA —
1.5–3 1 0/1 0 2 0/2 0
43 6 6/6 100 7 3/7 43
Transfectants (w.t. ALCAM
þDN-ALCAM)
o1.5 9 2/9 22 7 2/7 29
1.5–3 0 NA — 1 1/1 100
43 0 NA — 11 8/11 73
The malignant properties of control BLM cells (expressing wild-type ALCAM) and transfected BLM cells (expressing DN-ALCAM in addition to wild-
type ALCAM) were analyzed for subcutaneous tumor growth and spontaneous metastasis in nude mice. Series of five animals were subcutaneously
inoculated with one line of melanoma cells as described in Materials and Methods. In a first experiment all matched series of animals were
simultaneously euthanized when one of the primary tumors reached the maximally tolerated size (this occurred after 42 d; incubation). In successive
experiments the incubation time was either limited to 32 d to collect more small tumors (o 3 g) for the control group or prolonged to 48 and 52 d to
achieve maximally tolerated tumor size in the series of BLM/DN-ALCAM tumors. The four series of control cells included BLM cell clones transfected
with the empty expression vector and untransfected BLM cells. The six series of transfected BLM/DN-ALCAM cells were executed with two of the
independently isolated cell clones (BLM/DN-ALCAM-1, -2). Tumor take in all animal series was 100%. In four cases (two controls and two transfectants)
the quality of the lung tissue did not allow microscopic analysis to score metastasis and these animals were not included in the table.
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tumor growth in a nude mouse model (Fig 5) and lowers the
threshold of subcutaneous tumor growth prior to metastasis
(Tables I and II). Taken together with previously published
reports (Van Kempen et al, 2000, 2001), the data provide
evidence that stepwise modulation of ALCAM-mediated cell
adhesion is involved in melanoma metastasis.
Reduction of ALCAM-mediated adhesion via DN-ALCAM
resulted in less adhesive and more mobile tumor cells. In
cultured skin reconstructs (Fig 4), metastatic BLM/CTRL
cells (expressing wild-type ALCAM) disrupted the epidermal
architecture as a result of massive and expansive growth in
the epidermis and moderately invaded the upper dermis.
In contrast, BLM/DN-ALCAM cells (expressing DN-ALCAM
in addition to wild-type ALCAM) steadily migrated deep into
the dermis as single cells or slender tumor cell strands,
leaving the epidermis intact. The biological behavior of
BLM/CTRL cells strikingly resembled the properties of the
human vertical growth phase melanoma cell line WM793 in
skin reconstructs, which displayed comparable cell clusters
within the epidermis, at the epidermal–dermal junction and
upper dermis (Meier et al, 2000). On the other hand, the
biological behavior of BLM/DN-ALCAM cells closely re-
sembled the highly metastatic human melanoma cell line
WM852 with its typical aggressive, vertical, invasive growth
of individual melanoma cells deep into the dermal part of
the skin reconstructs (Meier et al, 2000).
When inoculating cells co-expressing endogenous wild-
type ALCAM and ectopic DN-ALCAM into nude mice, the
reduced subcutaneous tumor growth observed (Fig 5A)
could not be explained by changes in either tumor cell
proliferation, necrosis, or apoptosis (Fig 5B). A feasible
explanation for the reduced subcutaneous growth would be
that BLM/DN-ALCAM cells were continuously released
even before outgrowth of a substantial subcutaneous tumor
mass. The observation that subcutaneous inoculation of
BLM/DN-ALCAM cells into nude mice already gave rise to
the formation of lung metastases at a relatively small tumor
mass, is in agreement with this explanation. As BLM/CTRL
cells did not form lung metastases at these small sizes
(Tables I and II), we conclude that the decreased sub-
cutaneous tumor growth is caused by rapid and continuous
release of cells from the subcutaneous tumor as a con-
sequence of less adhesive and more motile tumor cells.
Thus, our data suggest that ALCAM-mediated adhesion
represents a rate-limiting step in the transition from
expansive primary tumor growth to invasion of the
surrounding tissue, i.e., the initial step in the metastatic
cascade.
Considering their relative structures, it has not escaped
our notice that DN-ALCAM may be generated from wild-
type ALCAM by proteolysis (see cell adhesion model; Fig 1).
It is generally known that expression and activity of a variety
of extracellular and cell-surface proteinases are upregulated
in tumors and that elevated proteinase levels strongly
correlate with the in vitro invasive behavior of tumor cells,
including melanoma cells (Werb, 1997; Lochter et al, 1998;
Hofmann et al, 2000a; McCawley and Matrisian, 2000,
Sternlicht and Werb, 2001; Coussens et al, 2002; Egeblad
and Werb, 2002; Dennhofer et al, 2003). Progression of
human cutaneous primary melanoma was reported to
coincide with increased expression and activation of matrix
metalloproteinase (MMP)-2 (Kurschat et al, 1999, 2002;
Hofmann et al, 2000b). Although MMP are best known for
their capacity to cleave virtually all extracellular matrix
proteins, recent literature reports also demonstrate their
involvement in the release of growth factors that are
sequestered in the matrix, cleavage of growth factor
receptors on the cell plasma membrane (Werb, 1997;
Bergers and Coussens, 2000), and in modulating cellular
adhesion and cell mobility (Kajita et al, 2001; Mechtershei-
mer et al, 2001; Noe¨ et al, 2001). Specific shedding of
membrane receptors by these proteinases may be an
integral part of cell–cell communication and essential for
early stages of neoplastic progression (Vu and Werb, 2000).
We like to propose that the applied, recombinant expres-
sion of DN-ALCAM in BLM cells may be a paradigm of
proteolytic mimicry. Expression of recombinant degradation
products may stabilize short-lived cleavage intermediates
and, thus, facilitate the biological analysis of highly
transitory cell responses. It will be worthwhile to clarify the
conjectured role of proteolysis in modulating ALCAM
functions.
Because attenuation of ALCAM-mediated cell–cell adhe-
sion in human melanoma cells positively contributes to
metastasis, the question arises why and how de novo
ALCAM expression in VGP melanoma contributes to tumor
Table II. Effect of DN-ALCAM expression on spontaneous metastasis of BLM xenografts in nude mice
BLM cells
Primary tumor
size (weight, g)
Animals with lung
metastasis
Score of metastatic
lesions in lung sections
#/total
Fraction of
total (%) Total #
Mean # per
positive animal
Controls (w.t. ALCAM) o3 0/5 0 0 0
43 9/13 69 29 3.2
Transfectants
(w.t. ALCAMþDN-ALCAM)
o3 5/17 29 21 4.2
43 8/11 73 41 5.1
The data from Table I were pooled on the basis of subcutaneous tumor size. The comparison of controls (w.t. ALCAM) and transfectants (w.t.
ALCAMþDN-ALCAM) revealed a statistically significant increase in metastasic lesions derived from small tumors (o3 g) of the DN-ALCAM transfectants
(po0.05; w2 test). Additionally, the number of metastatic lesions counted in lung sections by microscopic analysis is indicated as well as the average
number of lesions per positive animal.
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progression. All attempts failed to select for BLM cells with
diminished ALCAM expression via application of repeated
cycles of FACS selection and anti-sense techniques (our
unpublished results), suggesting that ALCAM could be
required for sustained cell proliferation in these cells.
Additionally, developmental biology studies show that
ALCAM expression generally occurs in cells undergoing
proliferation: e.g., ALCAM is expressed in the growth cone
of extending neurons (Corbel et al, 1992; Sekine-Aizawa
et al, 1998) and in hematopoietic progenitor cells with high
proliferative potential (Uchida et al, 1997). Furthermore, the
avian orthologue of ALCAM, DM-GRASP, may be involved
in the growth of v-rel-positive tumor cells (Zhang et al,
1995). In the metastatic cascade analyzed here, attenuation
of the ALCAM cell adhesion function apparently impairs
primary tumor growth and favors actual cell release from
the primary tumor. Although tumor growth and metastasis
are generally related, our observations indicate that cell
proliferation and invasion may represent disconnected
phenotypic events. This phenomenon is a rather rare or
neglected aspect in metastasis research, but it could well
relate to the aggressive malignancy of melanoma and the
notorious metastatic potential of thin lesions. Tuning cell
growth and invasion is inherent to normal development and,
presumably, requires coordination via molecular switches. If
ALCAM would represent such a switch, its expression in
melanoma progression could reflect the pathological onset
of a genomic program that coordinates cellular proliferation
and migration. This hypothesis is open for further experi-
mental verification.
Materials and Methods
Cell lines The adherent human melanoma cell lines BLM and 530
(Van Muijen et al, 1991) were grown as monolayers in Dulbecco’s
modified Eagle’s medium (DMEM) as described before (Degen
et al, 1998). BLM cells transfected with amino-terminally truncated
ALCAM (DN-ALCAM) and 530 cells transfected with wild-type
ALCAM were cultured as described previously (Degen et al, 1998;
Van Kempen et al, 2001). Regular tests confirmed that cell lines
were free of mycoplasma contamination.
Transfection FuGENE-6 transfection reagent (Roche Diagnostics,
Mannheim, Germany) was used to transfect the human melanoma
cell lines according to the manufacturer’s protocol. In brief, a
mixture of FuGENE-6 and circular DNA (3 mL and 0.5 mg,
respectively) was added drop wise to a 40% confluent monolayer
in medium. After 48 h, medium was replaced with selection
medium (mediumþ 1 mg per mL G418). Neomycin resistant
colonies were expanded and maintained in medium supplemented
with 0.5 mg per mL G418 (Life Technologies, Breda, The Nether-
lands).
Flow cytometry: Cell surface expression and aggregation
assay Cells (2  105) were incubated with mouse monoclonal
antibody AZN-L50 that recognizes the membrane proximal ALCAM
domains D4-5 (Nelissen et al, 2000a; Van Kempen et al, 2001) at
4 mg per mL in (phosphate-buffered saline (PBS) containing 1%
bovine serum albumin (BSA) and 0.05% NaN3) for 30 min at 41C.
Cells were washed three times with this buffer and further
incubated with FITC-conjugated goat anti-mouse IgG antibody
(Dako, Glostrup, Denmark) for 30 min at 41C. After washing,
positive cells were detected using an FACScan (Becton Dickinson,
Mountain View, California) and the mean fluorescence intensity
was determined.
The aggregation capacity of human melanoma cell lines was
measured by a double colored assay as described previously
(Degen et al, 1998). Briefly, two separate cell suspensions were
labeled fluorescent green or fluorescent red with 5,6-sulfofluor-
escein diacetate (50 mg per mL in DMEM/fetal calf serum (FCS),
Molecular Probes, Junction City, Oregon) or hydroethidine (40 mg
per mL in DMEM/FCS, Polysciences, Warrington, Pennsylvania),
respectively. Following extensive washing, cells were mixed in
equal amounts and allowed to aggregate at 371C for 30 min. After
incubation, cells were fixed by adding paraformaldehyde to a final
concentration of 0.5% (v/v) and subsequently analyzed by flow
cytometry. Aggregation capacity was expressed as the percentage
of double colored events of the total of red plus green events.
Wound-healing assay Using a pipette tip, a ‘‘wound’’ was
inflicted to a confluent monolayer of cells. After removal of the
detached cells by washing with warm medium, the Petri dishes
were returned to 371C. The gap width was measured using an
Olympus BH-2 microscope and DP10 camera (Olympus, Ham-
burg, Germany) after 2 h to allow spreading of the cells and every
2 h thereafter. Images were analyzed using AnalySIS software
(Soft Imaging Systems, Mu¨nster, Germany). The duration of the
experiment did not exceed the doubling time of the cells tested (18
h, unpublished data). The gap width was plotted as function of
time.
Cell invasion in three-dimensional skin reconstructs Invasion
of melanoma cells was tested in skin reconstructs as described
previously (Meier et al, 2000). In brief, human foreskin dermal
fibroblasts in rat tail collagen were placed on a precast collagen gel
on day 0. During 6 d of submerged culture, constriction of the
collagen gels yielded a concave surface, which served as a cradle
for seeding of epidermal and melanocytic cells. Melanoma cells
mixed with keratinocytes at a 1:5 ratio were seeded onto the
dermal constructs (day 6). After another 5 d of submerged culture
(day 11), the gel constructs were lifted to the air–liquid level for an
additional 10 d to allow stratification of epidermal keratinocytes.
The reconstructs were then harvested (day 21), fixed in parafor-
maldehyde, embedded in paraffin, sectioned, and stained with
HMB45 melanocytic marker. Normal melanocytes localized within
the stratum basale of the epidermis are positive. BLM cells are
HMB45 negative.
In vivo local tumor growth and metastasis Animal studies were
approved by the Institutional Review Board for animal experi-
ments. Female BALB/c athymic nude mice (nu/nu) were bred in the
nude mice facility of the Central Animal Laboratory, University
of Nijmegen, The Netherlands. Animals were kept under specified
pathogen-free conditions and used when 4–6 wk old.
Tumor cells were harvested using trypsin/EDTA, washed in PBS
and suspended in PBS at 2.5  107 cells per mL and 100 mL of cell
suspension was inoculated subcutaneously above the lateral tho-
racic wall (Van Muijen et al, 1991). Mice were inspected twice a week
for general condition and local tumor growth was monitored. The
animals were euthanized at the indicated times. Following
euthanization, lungs were prepared with TissueTech Sakuro
compound (Bayer B.V., Mijdrecht, The Netherlands), fixed in 4%
neutral formalin and finally embedded in paraffin for microscopic
examination of hematoxylin- and eosin-stained 4 mm sections.
In situ proliferation and apoptosis detection Tumor cell pro-
liferation was detected via immunohistochemical staining of
paraffin-embedded tumors. The mouse monoclonal antibody
MIB-1 (Immunotech, Beckman Coulter, Mijdrecht, The Nether-
lands) is directed against the Ki67 nuclear protein, which is
expressed in proliferating cells during late G1-, S-, M-, and G2-
phases of the cell cycle, whereas cells in the G0 (quiesent phase)
are negative for this protein (Gerdes et al, 1984). Tumor sections
(5 mm) were deparaffinated in xylene (two times 5 min) and,
subsequently, in absolute ethanol (three times 5 min). Slides were
boiled twice in 0.1 M citrate buffer (pH 6.0) for 5 min in a microwave
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and rinsed with PBS supplemented with 0.1% BSA. Following
blocking of non-specific sites via incubation in normal horse serum
(Vector Laboratories, Burlingame, California) for 20 min, sections
were incubated with monoclonal antibody (mAb) anti-MIB-1 for 1 h
at room temperature. After washing the slides with PBS/0.1% BSA,
they were incubated with biotin-conjugated horse anti-mouse
antibody (Dako) for 30 min. After subsequent washing with PBS/
0.1% BSA, the avidin–biotin complex was formed using the
Vectastain elite kit (Vector Laboratories) and developed by
incubating the slides with diaminobenzidine (Pierce, Rockford,
Illinois) for 10 min. Sections were briefly counterstained with
hemateine. Using the Weibel-2 graticule (Graticules Ltd, Kent, UK),
the proliferation index was scored by counting MIB-1-positive
cells. Randomly chosen fields within one tumor lesion were
counted until the average of MIB-1-positive cells did not change
after counting additional fields. Generally, after scoring seven
fields, a stable average was obtained.
Apoptosis was detected by in situ TdT-mediated dUTP nick end
labeling (TUNEL). Tumor sections of 5 mm were deparaffinated in
xylene, rehydrated, washed in PBS, and digested with 40 mg per
mL Proteinase K (Sigma, St Louis, Missouri) in PBS for 15 min
at 251C. The TUNEL reaction was performed according to the
manufacturer’s instructions (Intergen, Oxford, UK), developed with
diaminobenzidine (Pierce) and counterstained with 0.5% (w/v)
methyl green in 0.1 M sodium acetate, pH 4.0. The apoptotic index
was determined on five or more fields (corresponding to 41500
cells) from each tumor lesion. The fields were randomly chosen
within regions with scattered apoptosis as described (Toft and
Arends, 1997). The ‘‘STATGRAPHICS plus 4.1’’ software package
was used to perform statistical calculations (one-way analysis of
variance).
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